Rekurrenz der IgA-nephropathie nach nierentransplantation

verfasst von: Christos Bantis, P. J. Heering, Cornelia Blume, Sendogan Aker, Magdalena Siekierka, B. Grabensee, Katrin Ivens
Abstract: Aim of the study: In the present study, we evaluated risk factors for the development and the clinical course of recurrent IgA nephropathy (IgAN) after renal transplantation. Patients and methods: We analyzed n = 125 patients who were transplanted from 1986 to 2004 and had biopsy-proven IgAN as primary disease and n = 250 renal allograft recipients with other primary diseases. The mean follow-up period was 6.0 ± 3.6 years. Results: During follow-up, IgAN recurrence was diagnosed by transplant biopsy in n = 24 patients (19% of the cohort, 44% of the patients who underwent a transplant biopsy for any reason after the first 6 months post transplantation). The mean time from renal transplantation to the development of microscopic hematuria and histologic confirmation of IgAN recurrence was 2.8 ± 1.8 and 4.7 ± 2.6 years, respectively. Patients with biopsy-confirmed IgAN recurrence were younger compared to patients with biopsy-excluded or with no clinical signs of recurrence (37.6 ± 11 vs 44.4 ± 12 years, p < 0.05). In the Cox regression analysis, a 34% higher recurrence risk was demonstrated for every decade of age (HR 0.66, 95% CI: 0.45 - 0.96, p < 0.05). IgAN recurrence was not associated with the type of the graft (cadaveric or living donor), HLA constellation, number of acute rejection episodes or immunosuppressive and antihypertensive medications (NS). Graft survival was not influenced by the presence of IgAN recurrence (NS). There was no significant difference in graft survival between patients with IgAN and other primary diseases (NS). Conclusion: IgAN recurrence is a common complication, especially in younger renal transplant recipients, but has no impact on graft survival.
Externe Organisation(en): Universitätsklinikum Düsseldorf
Typ: Artikel
Journal: Nieren- und Hochdruckkrankheiten
Band: 36
Seiten: 81-86
Anzahl der Seiten: 6
ISSN: 0300-5224
Publikationsdatum: 03.2007
Publikationsstatus: Veröffentlicht
Peer-reviewed: Ja
ASJC Scopus Sachgebiete: Innere Medizin, Nephrologie
Elektronische Version(en): https://doi.org/10.5414/nhp36081 (Zugang: Geschlossen)

BibTeX

@article{ef8a43611da5475f92533638e63e0092,
title = "Rekurrenz der IgA-nephropathie nach nierentransplantation",
abstract = "Aim of the study: In the present study, we evaluated risk factors for the development and the clinical course of recurrent IgA nephropathy (IgAN) after renal transplantation. Patients and methods: We analyzed n = 125 patients who were transplanted from 1986 to 2004 and had biopsy-proven IgAN as primary disease and n = 250 renal allograft recipients with other primary diseases. The mean follow-up period was 6.0 ± 3.6 years. Results: During follow-up, IgAN recurrence was diagnosed by transplant biopsy in n = 24 patients (19% of the cohort, 44% of the patients who underwent a transplant biopsy for any reason after the first 6 months post transplantation). The mean time from renal transplantation to the development of microscopic hematuria and histologic confirmation of IgAN recurrence was 2.8 ± 1.8 and 4.7 ± 2.6 years, respectively. Patients with biopsy-confirmed IgAN recurrence were younger compared to patients with biopsy-excluded or with no clinical signs of recurrence (37.6 ± 11 vs 44.4 ± 12 years, p < 0.05). In the Cox regression analysis, a 34% higher recurrence risk was demonstrated for every decade of age (HR 0.66, 95% CI: 0.45 - 0.96, p < 0.05). IgAN recurrence was not associated with the type of the graft (cadaveric or living donor), HLA constellation, number of acute rejection episodes or immunosuppressive and antihypertensive medications (NS). Graft survival was not influenced by the presence of IgAN recurrence (NS). There was no significant difference in graft survival between patients with IgAN and other primary diseases (NS). Conclusion: IgAN recurrence is a common complication, especially in younger renal transplant recipients, but has no impact on graft survival.",
keywords = "IgA nephropathy, Kidney transplantation, Kidney transplantation: complications, Recurrence of primary disease, Renal graft survival",
author = "Christos Bantis and Heering, {P. J.} and Cornelia Blume and Sendogan Aker and Magdalena Siekierka and B. Grabensee and Katrin Ivens",
year = "2007",
month = mar,
doi = "10.5414/nhp36081",
language = "Deutsch",
volume = "36",
pages = "81--86",
journal = "Nieren- und Hochdruckkrankheiten",
issn = "0300-5224",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "3",
}